Abstracts tagged "risk and uric acid"

Abstract Number: 2076 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Allopurinol Versus Febuxostat in Preventing Incident Dementia in the Elderly
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Previous studies of hyperuricemia and dementia have provided contradictory findings, ranging from reduced to increased risk. Our objective was to assess the comparative effectiveness…
Abstract Number: 3167 • 2015 ACR/ARHP Annual Meeting
Association of the Apolipoprotein A1-C3-A4 Gene Cluster with the Risk of Gout: Evidence for a Causal Role in Gout
Tony R. Merriman¹, Amanda Phipps-Green², Ruth Topless², Malcolm D. Smith³, Catherine Hill⁴, Susan Lester⁴, Maureen Rischmueller⁵, Matthijs Janssen⁶, Tim Jansen⁷, Leo A. Joosten⁸, Timothy Radstake⁹, Philip L. Riches¹⁰, Anne-Kathrin Tausche¹¹, Frederic Lioté¹², Alex So^13,14, Andre M. van Rij², Gregory T. Jones¹⁵, Sally McCormick¹⁶, Andrew Harrison², Lisa K. Stamp¹⁷, Nicola Dalbeth¹⁸ and Humaira Rasheed¹⁶, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Rheumatology, Repatriation General Hospital, Adelaide, Australia, ⁴Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ⁵Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, ⁶Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁷P O Box 581, Haarlem, Netherlands, ⁸Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁰Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹¹Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹²Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹³Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹⁴Department of Rheumatology, CHUV, Lausanne, Switzerland, ¹⁵Surgery, University of Otago, Dunedin, New Zealand, ¹⁶Department of Biochemistry, University of Otago, Dunedin, New Zealand, ¹⁷Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ¹⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Gout is caused by an inflammatory response to monosodium urate (MSU) crystals and is associated with elevated triglyceride and very low density lipoprotein levels.…
Abstract Number: 160 • 2013 ACR/ARHP Annual Meeting
Association Analysis Of The Organic Anion Transporter 4 and Urate Transporter 1 Locus With Gout In New Zealand Case-Control Sample Sets Reveals Multiple Ancestral-Specific Effects
Tony R. Merriman¹, Amanda Phipps-Green¹, Jade E. Hollis-Moffatt², Marilyn E. Merriman¹, Ruth Topless¹, Grant Montgomery³, Brett Chapman³, Lisa K. Stamp⁴, Nicola Dalbeth⁵ and Tanya Flynn², ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Queensland Institute of Medical Research, Brisbane, Australia, ⁴University of Otago, Christchurch, New Zealand, ⁵Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: There are genetic variants in urate transporters SLC22A11 (OAT4) and SLC22A12 (URAT1) that influence serum urate levels in European Caucasian. However, there is no…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].